摘要
目的 探讨艾司西酞普兰与氯米帕明对强迫症患者临床疗效和生活质量的影响.方法 将60例强迫症患者随机分为两组,每组30例,研究组口服艾司西酞普兰治疗,对照组口服氯米帕明治疗.观察8周.于治疗前及治疗8周末采用Yale-Brown强迫症量表、汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效,生活质量综合评定问卷评定生活质量,副反应量表评定不良反应.结果 治疗后两组Yale-Brown强迫症量表、汉密顿抑郁量表、汉密顿焦虑量表评分均较治疗前有显著下降（P＜0.01）,同期两组间比较差异均无显著性（P＞0.05）;治疗8周末,研究组显效率73.3%、有效率86.7%,对照组分别为70.0%、83.3%,两组比较差异无显著性（P＞0.05）.治疗后研究组生活质量综合评定问卷躯体功能、心理功能、社会功能维度评分均显著高于对照组（P＜0.05）.结论 艾司西酞普兰与氯米帕明治疗强迫症总体疗效相当,但艾司西酞普兰对提高患者的生活质量显著优于氯米帕明.
Objective To explore the efficacy, safety and influences on quality of life of escitalopram and clomipramine in patients with obsessive compulsive disorder （（）CD）. Methods Sixty OCD patients were randomly assigned to two groups of 30 ones each, research group took orally escitalopram and control group did clomipramine for 8 weeks. Before treatment and at the end of the 8^th week, efficacies were assessed with the Yale Brown Obsessive-compulsive Scale （Y BOCS）, Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA）, quality of life with the Generic Quality of Life Inventory-74 （GQOLI-74） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results After treatment, the Y-BOCS, HAMD, HAMA score of both groups lowered more significantly compared with pretreatment （P〈0. 01）, there were no significant differences in contemporaneous group comparisons （P〉0.05） ; at the end of the 8^th week, obvious effective and effective rate were 73.3% and 86.7% in re search and 70.0% and 83.3% in control group respectively, which showed no significant difference （P〉 0.05）. After treatment somatic, psychological and social function score of the GQOLI-74 were significantly higher in research than control group （P〈0.05）. Conclusion Both escitalopram and clomipramine have equivalent total efficacy in the treatment of the OCD, but eseitalopram improves patients＇ quality of life more notably compared with clomipramine treatment.
出处
《临床心身疾病杂志》
CAS
2012年第4期367-369,共3页
Journal of Clinical Psychosomatic Diseases
